加拿大儿科药物法规改革:临床和准入的当务之急。

Q2 Medicine
Charlotte Moore Hepburn, Allison A Chang, Deborah M Levy
{"title":"加拿大儿科药物法规改革:临床和准入的当务之急。","authors":"Charlotte Moore Hepburn, Allison A Chang, Deborah M Levy","doi":"10.12927/hcpol.2023.27157","DOIUrl":null,"url":null,"abstract":"<p><p>Children deserve the same high standards for drug safety, efficacy and access as adults. Unfortunately, Canada lags behind leading international regulators in implementing reforms to ensure access to paediatric medications. Paediatric regulations, also known as paediatric rules in the US, include a mandate to submit paediatric data in all new drug applications when paediatric use can be anticipated. Absent paediatric regulations, many medications with paediatric-specific indications in other countries remain \"off-label\" for Canadian children. In addition to concerns related to off-label drug safety, the absence of paediatric indications prohibits appropriate paediatric-specific health technology assessments and limits the evidence-based listing of paediatric medications on public and private formularies.</p>","PeriodicalId":39389,"journal":{"name":"Healthcare Policy","volume":"19 1","pages":"54-64"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519333/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reforming Paediatric Drug Regulations in Canada: A Clinical and an Access Imperative.\",\"authors\":\"Charlotte Moore Hepburn, Allison A Chang, Deborah M Levy\",\"doi\":\"10.12927/hcpol.2023.27157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Children deserve the same high standards for drug safety, efficacy and access as adults. Unfortunately, Canada lags behind leading international regulators in implementing reforms to ensure access to paediatric medications. Paediatric regulations, also known as paediatric rules in the US, include a mandate to submit paediatric data in all new drug applications when paediatric use can be anticipated. Absent paediatric regulations, many medications with paediatric-specific indications in other countries remain \\\"off-label\\\" for Canadian children. In addition to concerns related to off-label drug safety, the absence of paediatric indications prohibits appropriate paediatric-specific health technology assessments and limits the evidence-based listing of paediatric medications on public and private formularies.</p>\",\"PeriodicalId\":39389,\"journal\":{\"name\":\"Healthcare Policy\",\"volume\":\"19 1\",\"pages\":\"54-64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519333/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Healthcare Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12927/hcpol.2023.27157\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpol.2023.27157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

儿童在药物安全、疗效和获取方面应享有与成年人同等的高标准。不幸的是,加拿大在实施改革以确保获得儿科药物方面落后于领先的国际监管机构。儿科法规,在美国也被称为儿科规则,包括在可以预期儿科使用的情况下,在所有新药申请中提交儿科数据的授权。在没有儿科法规的情况下,其他国家许多具有儿科特定适应症的药物对加拿大儿童来说仍然是“标签外”的。除了与标示外药物安全相关的担忧外,由于缺乏儿科适应症,无法进行适当的儿科特定健康技术评估,并限制了儿科药物在公共和私人处方中的循证上市。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reforming Paediatric Drug Regulations in Canada: A Clinical and an Access Imperative.

Children deserve the same high standards for drug safety, efficacy and access as adults. Unfortunately, Canada lags behind leading international regulators in implementing reforms to ensure access to paediatric medications. Paediatric regulations, also known as paediatric rules in the US, include a mandate to submit paediatric data in all new drug applications when paediatric use can be anticipated. Absent paediatric regulations, many medications with paediatric-specific indications in other countries remain "off-label" for Canadian children. In addition to concerns related to off-label drug safety, the absence of paediatric indications prohibits appropriate paediatric-specific health technology assessments and limits the evidence-based listing of paediatric medications on public and private formularies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Healthcare Policy
Healthcare Policy Medicine-Health Policy
CiteScore
3.20
自引率
0.00%
发文量
42
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信